Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
Why Choose New Results Medical Weight Loss in Phoenix
Not intended for pregnant or lactating individuals unless advised by a healthcare provider
R While Gilbert syndrome itself is considered benign, reduced UGT1A1 activity also impairs glucuronidation of drugs (irinotecan toxicity is dramatically increased in UGT1A1*28 homozygotes) and estrogens
L.DuanH.et al
At 2.5mg (8.3 units), precision is challenging without specialized syringes